Critical Contrast: Guided Therapeutics (GTHP) versus The Competition

Guided Therapeutics (OTCMKTS:GTHP) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Guided Therapeutics to similar businesses based on the strength of its analyst recommendations, risk, valuation, profitability, institutional ownership, dividends and earnings.

Risk and Volatility

Guided Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ competitors have a beta of 17.00, indicating that their average share price is 1,600% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Guided Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	271	804	2020	109	2.61

As a group, “Electromedical equipment” companies have a potential upside of 3,351.31%. Given Guided Therapeutics’ competitors higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Guided Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-331.31%	-92.24%	-30.04%

Earnings and Valuation

This table compares Guided Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-6.67
Guided Therapeutics Competitors	$1.00 billion	$85.30 million	5.55

Guided Therapeutics’ competitors have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by company insiders. Comparatively, 14.8% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Guided Therapeutics competitors beat Guided Therapeutics on 7 of the 10 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.